Motiv8 Investments LLC Decreases Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Motiv8 Investments LLC trimmed its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 10.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 69,245 shares of the biotechnology company’s stock after selling 8,401 shares during the period. Motiv8 Investments LLC’s holdings in Heron Therapeutics were worth $106,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of HRTX. Wealth Enhancement Advisory Services LLC increased its position in shares of Heron Therapeutics by 21.2% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 7,927 shares during the period. King Wealth Management Group grew its position in shares of Heron Therapeutics by 52.3% in the 3rd quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company’s stock worth $46,000 after buying an additional 8,000 shares during the last quarter. Glenmede Trust Co. NA lifted its stake in Heron Therapeutics by 49.6% in the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 10,578 shares during the period. Principal Financial Group Inc. increased its position in Heron Therapeutics by 10.6% during the 4th quarter. Principal Financial Group Inc. now owns 113,560 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 10,909 shares during the period. Finally, Zacks Investment Management increased its position in shares of Heron Therapeutics by 2.4% during the third quarter. Zacks Investment Management now owns 475,575 shares of the biotechnology company’s stock valued at $946,000 after buying an additional 11,320 shares during the period. 80.01% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on HRTX. StockNews.com cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 29th. Needham & Company LLC restated a “buy” rating and set a $4.00 price target on shares of Heron Therapeutics in a report on Wednesday, December 4th.

Heron Therapeutics Stock Performance

NASDAQ:HRTX opened at $1.71 on Thursday. The stock’s fifty day moving average is $1.66 and its 200 day moving average is $1.71. The firm has a market capitalization of $260.08 million, a PE ratio of -9.50 and a beta of 1.60. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.93.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.